O
Oleg Iartchouk
Researcher at Novartis
Publications - 12
Citations - 1189
Oleg Iartchouk is an academic researcher from Novartis. The author has contributed to research in topics: Mycobacterium tuberculosis & Tuberculosis. The author has an hindex of 9, co-authored 12 publications receiving 992 citations. Previous affiliations of Oleg Iartchouk include Partners HealthCare & Harvard University.
Papers
More filters
Journal ArticleDOI
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection
Christopher B. Ford,Philana Ling Lin,Michael R. Chase,Rupal R. Shah,Oleg Iartchouk,James E. Galagan,James E. Galagan,Nilofar Mohaideen,Thomas R. Ioerger,James C. Sacchettini,Marc Lipsitch,JoAnne L. Flynn,Sarah M. Fortune +12 more
TL;DR: It is shown that Mtb continues to acquire mutations during disease latency, which may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence of isoniaZid resistance.
Journal ArticleDOI
A rare penetrant mutation in CFH confers high risk of age-related macular degeneration
Soumya Raychaudhuri,Oleg Iartchouk,Kimberly A Chin,Perciliz L. Tan,Albert K. Tai,Stephan Ripke,Stephan Ripke,Sivakumar Gowrisankar,Soumya Vemuri,Kate T. Montgomery,Yi Yu,Robyn Reynolds,Donald J. Zack,Betsy Campochiaro,Peter A. Campochiaro,Nicholas Katsanis,Mark J. Daly,Mark J. Daly,Johanna M. Seddon,Johanna M. Seddon +19 more
TL;DR: A rare, high-risk CFH haplotype with a c.3628C>T mutation that resulted in an R1210C substitution is discovered, which suggests that loss-of-function alleles at CFH are likely to drive AMD risk.
Journal ArticleDOI
Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value.
Maha R. Farhat,Razvan Sultana,Oleg Iartchouk,Sam Bozeman,James E. Galagan,Peter Sisk,Christian Stolte,Hanna Nebenzahl-Guimaraes,Karen R. Jacobson,Alexander Sloutsky,Devinder Kaur,James E. Posey,Barry N. Kreiswirth,Natalia Kurepina,Leen Rigouts,Elizabeth M. Streicher,Tommie C. Victor,Robin M. Warren,Dick van Soolingen,Megan Murray +19 more
TL;DR: Data suggest that a comprehensive M. tuberculosis drug resistance diagnostic will need to allow for a high dimension of mutation detection and support the hypothesis that currently unknown genetic determinants, potentially discoverable by whole-genome sequencing, encode resistance to second-line tuberculosis drugs.
Journal ArticleDOI
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.
Angelo Grauel,Beverly Nguyen,David A. Ruddy,Tyler Laszewski,Stephanie Schwartz,Jonathan Chang,Julie Chen,Michelle Piquet,Marc Pelletier,Zheng Yan,Nathaniel D. Kirkpatrick,Jincheng Wu,Antoine deWeck,Markus Riester,Matt Hims,Felipe Correa Geyer,Joel Wagner,Kenzie MacIsaac,James Deeds,Rohan Diwanji,Pushpa Jayaraman,Yenyen Yu,Quincey Simmons,Shaobu Weng,Alina Raza,Brian Minie,Mirek Dostalek,Pavitra Chikkegowda,Vera M. Ruda,Oleg Iartchouk,Naiyan Chen,Raphael Thierry,Joseph X. Zhou,Iulian Pruteanu-Malinici,Claire Fabre,Jeffrey A. Engelman,Glenn Dranoff,Viviana Cremasco +37 more
TL;DR: This study shows that neutralization of TGFβ in vivo leads to remodeling of CAF dynamics, greatly reducing the frequency and activity of the myofibroblast subset, while promoting the formation of a fibroblast population characterized by strong response to interferon and heightened immunomodulatory properties.
Journal ArticleDOI
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection
Daniel S. Herman,G Kees Hovingh,G Kees Hovingh,Oleg Iartchouk,Heidi L. Rehm,Heidi L. Rehm,Raju Kucherlapati,Jonathan G. Seidman,Christine E. Seidman,Christine E. Seidman +9 more
TL;DR: This work developed a hybridization enrichment strategy for DNA capture that uses PCR products as subgenomic traps and applied this strategy to 115 kilobases of the human genome encompassing 47 genes implicated in cardiovascular disease.